Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group

By sjmartinez • November 3, 2023

Berthelsen DB, Simon LS, Ioannidis JPA, Voshaar M, Richards P, Goel N, Strand V, Nielsen SM, Shea BJ, Tugwell P, Bartlett SJ, Hazlewood GS, March L, Singh JA, Suarez-Almazor ME, Boers M, Stevens RM, Furst DE, Woodworth T, Leong A, Brooks PM, Flurey C, Christensen R; OMERACT Safety Working Group. Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group. Semin Arthritis Rheum. 2023 Oct 26;63:152288. doi: 10.1016/j.semarthrit.2023.152288. Epub ahead of print. PMID: 37918049.

Tags: Adverse events, Core outcome set, Harms, OMERACT, Publications, Rheumatology, rheumatology, safety

Consensus-based Recommendations on the Management of Immunosuppression After Squamous Cell Carcinoma Diagnosis in Kidney Transplant Recipients: An International Delphi Consensus Statement

Whitley MJ, Wang JX, Chapman J, de Vries APJ, Chandran S, Glennon CM, Madariaga HM, Carroll RP, Booth J, Concepcion B, Couzi L, De Serres[...]

A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease

Brownstein AJ, Lliang L, Channick R, Kim A, Saggar R. A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease. Eur Respir[...]

Indefinite for dysplasia in Barrett’s esophagus: definitely worth your attention

Muthusamy VR. Indefinite for dysplasia in Barrett's esophagus: definitely worth your attention. Gastrointest Endosc. 2026 Jan;103(1):84-86. doi: 10.1016/j.gie.2025.06.024. PMID: 41412705.